Cytokinetics presents data on CK-1827452

South San Francisco, CA, September 19, 2005 Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the company presented a scientific poster on CK-1827452, a novel small molecule activator of cardiac myosin, today at the 2005 Annual Heart Failure Society of America Meeting in Boca Raton, Florida. The moderated oral poster presentation highlighted data relating to the mechanism of action of CK-1827452 as well as its characterization in a heart failure model in animals. CK-1827452 is the first clinical drug candidate to arise from the company's cardiac myosin activator program, research that leverages Cytokinetics' expertise in cytoskeletal pharmacology and muscle contractility. CK-1827452 is currently the subject of a first-time-in-human Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of this novel drug candidate.

The poster titled, "Direct Activation of Cardiac Myosin by CK-1827452 Improves Cardiac Function in a Dog Heart Failure Model." [Poster Presentation #017] has been displayed today and will be presented at 5:45 pm ET by Fady Malik, M.D., Ph.D., F.A.C.C., Director, Cardiovascular Programs, Cytokinetics. The presentation details research directed to the discovery and optimization of small molecules that improve cardiac function in a manner consistent with the therapeutic hypothesis, specifically that improving cardiac contractility by directly activating cardiac myosin can potentially address the liabilities of current inotropic drugs. The data demonstrate that CK-1827452 selectively activates cardiac myosin. In cardiac myocytes, CK-1827452 increases contractility without changes in the cellular calcium transient, a finding consistent with its mechanism of action. In addition, CK-1827452 demonstrates an improvement in cardiac function and output, hemodynamics and efficiency in a dog model of heart failure in a manner that supports the therapeutic hypothesis.

The presen

Contact: Justin Jackson
Burns McClellan

Page: 1 2 3 4

Related biology news :

1. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions
2. SNM presents awards on Capitol Hill
3. ESA presents the sharpest ever satellite map of Earth
4. New book presents neurobiology from an evolutionary perspective
5. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
6. Childrens Hospital and Research Center-Oakland presents a new maternal diet study
7. USGS presents a world of science at GSA in Philadelphia
8. Childrens Hospital Boston presents at the 2006 American Academy of Pediatrics National Conference
9. DFG presents the 2006 MAK and BAT value list
10. Childrens Hospital Boston presents at the 2006 Pediatric Academic Societies annual meeting
11. Kereos presents at AAAS, discusses nanotech-based disease diagnosis and treatment

Post Your Comments:

(Date:6/11/2019)... ... June 12, 2019 , ... ... discovery services, Abveris plans to leverage the Geneious Biologics platform as a premium ... Chief Technology Officer at Abveris, says: “The Geneious team has done an excellent ...
(Date:6/6/2019)... (PRWEB) , ... June 05, 2019 , ... ... announces the opening of a new network station and service center in Mexico ... and 12th in the world — with more than $1.75 billion in pharmaceutical ...
(Date:6/4/2019)... ... 04, 2019 , ... Molecular Devices, a global leader in ... new President of Molecular Devices, replacing Greg Milosevich who has been appointed President ... Since joining Molecular Devices in a scientific engineering role, Ms. Murphy has held ...
Breaking Biology News(10 mins):
(Date:5/8/2019)... Calif. (PRWEB) , ... May 07, 2019 , ... Standing at 16.2 hands, Atlas is ... too, participating in a drill team and barrel racing, among other activities. When loping ... ligament. He went from being a busy horse to only being able to walk. ...
(Date:5/4/2019)... BROOK, N.J. (PRWEB) , ... May 03, 2019 ... ... electrophysiology, announces the release of the Diopsys® ffERG/Photopic Negative Response vision ... of glaucoma. , By 2050, it is estimated that 6.3 million Americans will ...
(Date:5/2/2019)... TORONTO (PRWEB) , ... May 02, 2019 , ... Stay ... pharma, biotech, medical device and food industries. Access to all webinars is free, so ... stay relevant in your field! , Visit http://www.xtalks.com to see our upcoming ...
(Date:4/25/2019)... ... ... an albino, deaf Great Dane. His owners rescued him when he was four months old ... hearing impairment, he was always an active and playful pup. Frank bonded with his brother, ... the two grew, playtime became rougher and Frank ended up injuring his right rear leg. ...
Breaking Biology Technology:
Cached News: